William J. Boyle

BioAtla (United States) — United States

Medicine · Health Sciences

37h-index29.4kcitations93works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(23), Bone Metabolism and Diseases(21), Bone health and treatments(17), NF-κB Signaling Pathways(12), CAR-T cell therapy research(10)

Publications93 total

Abstract 2693: BA3361, a tumor selective, conditionally active biologic (CAB) anti-nectin4-ADC with a novel NextGen linker system enhances therapeutic efficacy in pancreatic cancer
Cancer Research·2025
Abstract 296: Identification of novel senolytic targets and development of conditionally active biologic-based-drug conjugates for targeted senescence-associated secretory phenotype elimination <i>in vivo</i>
Cancer Research·2025
Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate
mAbs·2025· 9 citedOpen Access
Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate
Antibody Therapeutics·2025· 5 citedOpen Access
Abstract 1405: Development of a humanized anti-IL-22 antibody for cancer and inflammation therapy
Cancer Research·2024
Abstract 743: Using a novel NextGen linker system to generate a conditionally active biologic (CAB) anti-nectin4-ADC demonstrates improved efficacy in pancreatic PDX cancer models and improved tolerability and toxicity profile in non-human primates
Cancer Research·2024· 1 cited
Abstract 6340: Novel conditionally active tetravalent B7-H3 x CD3 T-cell engagers targeting solid tumors
Cancer Research·2024
Abstract 2969: Targeting novel senescence markers by conditionally active biologics eliminates senescence-associated secretory phenotype in <i>in vitro</i> and <i>in vivo</i> models
Cancer Research·2024
Abstract 744: Novel conditionally active biologic (CAB) tetravalent T-cell engagers targeting solid tumors
Cancer Research·2024· 1 cited
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
mAbs·2024· 19 citedOpen Access
1343 Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors
Regular and Young Investigator Award Abstracts·2023Open Access
1342 A novel dual CAB Nectin-4 x CD3 bispecific antibody targeting solid tumors
Regular and Young Investigator Award Abstracts·2023Open Access
Population pharmacokinetic and exposure-response safety analyses of mecbotamab vedotin (BA3011) in patients with advanced solid tumors.
Journal of Clinical Oncology·2023· 3 cited
Abstract 4795: Conditionally active biologics eliminates senescence cells in cancer and aging
Cancer Research·2023
Abstract 1879: A novel dual CAB nectin-4 x CD3 bispecific antibody targeting solid tumors
Cancer Research·2023
Abstract 6335: Developing anti-IL-22 therapeutics for inflammation and cancer
Cancer Research·2023
Abstract 1871: Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors
Cancer Research·2023· 1 cited
Abstract 1541: NextGen conditionally active biologic (CAB) anti-Nectin-4-ADC with improved stability and safety
Cancer Research·2023· 2 cited
Abstract B022: Targeting senescence cells in cancer and aging by conditionally active biologic therapeutics
Cancer Research·2023· 3 cited
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches
Proceedings of the National Academy of Sciences·2021· 43 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

David L. Lacey(17), Gwyneth Van(10), Robin Elliott(9), Sean Morony(8), Colin R. Dunstan(7), Josef Penninger(7), Hailing Hsu(7), Michael J. Kelley(7), Young‐Yun Kong(6), Ildiko Sarosi(6), Casey Capparelli(6), Susan McCabe(6), Sheila Scully(6), F. G. Bordwell(6), Paul J. Kostenuik(5), Gerhard Frey(5), Jay M. Short(5), W. Scott Simonet(4), Ulrich Feige(4), Irina Solovyev(4)